Unichem Laboratories Limited

UNICHEMLAB

INE351A01035

Pharmaceuticals

Delayed Bombay S.E. Other stock markets 10:31:57 23/05/2024 BST			5-day change	1st Jan Change
548.2 ^INR	-3.48%		+0.86%	+34.71%

03-29	Unichem Laboratories Limited Announces Board Resignations, Effective March 31, 2024	CI
03-27	Unichem Laboratories Chief Commercial and International Business Development Officer Steps Down	MT

Unichem Laboratories Limited Receives ANDA Approval for its Ranolazine Extended-Release Tablets, 500 Mg and 1,000 Mg from the United States Food and Drug Administration

March 17, 2023 at 06:06 am

Unichem Laboratories Limited announced that it has received ANDA approval for its Ranolazine Extended-Release Tablets, 500 mg and 1,000 mg from the United States Food and Drug Administration (USFDA) to market a generic version of Ranexa®? (ranolazine extended-release tablets) 500 mg and 1,000 mg, of Gilead Sciences Inc. Ranolazine Extended-Release Tablets, 500 mg, and 1,000 mg are indicated for the treatment of chronic angina. The product will be commercialized from Unichem's Goa Plant.

Latest news about Unichem Laboratories Limited

Unichem Laboratories Limited Announces Board Resignations, Effective March 31, 2024	03-29	CI
Unichem Laboratories Chief Commercial and International Business Development Officer Steps Down	03-27	MT
Unichem Laboratories Limited Announces Resignation of Santosh Mahil as Chief Commercial & International Business Development Officer	03-27	CI
Unichem Laboratories Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	02-05	CI
Indian Equities Close Marginally Higher Ahead of IT Earnings	01-11	MT
Unichem Laboratories Gets US FDA Approval for Generic Hypertension Drug	01-11	MT
Unichem Laboratories Limited Receives Anda Approval for Its Doxazosin Tablets USP, 1 Mg, 2 Mg, 4 Mg and 8 Mg	01-11	CI
Unichem Laboratories Completes Sale of Entire Stake in Optimus Drugs	12-06	MT
Unichem Laboratories Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023	11-01	CI
Ipca Laboratories Limited completed the acquisition of 19.29% stake in Unichem Laboratories Limited for INR 6 billion.	07/09/23	CI
Unichem Laboratories Gets US FDA Nod for Prasugrel Tablets	30/08/23	MT
Unichem Laboratories Limited Receives ANDA Approval for its Prasugrel Tablets USP, 5 Mg and 10 Mg from the United States Food and Drug Administration	29/08/23	CI
Unichem Laboratories Limited Announces the Resignation of Dilip Kunkolienkar as Member of the Audit Committee and Risk Management Committee of the Board of Directors	09/08/23	CI
Ipca Laboratories Acquires 33% Stake in Unichem for INR9.45 Billion	02/08/23	MT
Unichem Laboratories Trims Consolidated Net Loss in Fiscal Q1	14/07/23	MT
Unichem Laboratories Limited Reports Earnings Results for the First Quarter Ended June 30, 2023	14/07/23	CI
Unichem Laboratories Swings to Loss in Fiscal Q4	24/05/23	MT
Unichem Laboratories Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2023	23/05/23	CI
Transcript : Ipca Laboratories Limited, Unichem Laboratories Limited - M&A Call	25/04/23
Ipca Laboratories to Acquire 33% Stake in Unichem for INR10.3 Billion	25/04/23	MT
INDIA STOCKS-Indian shares flat ahead of key earnings; IT, pharma stocks slide	25/04/23	RE
INDIA STOCKS-Indian shares flat ahead of key earnings; IT, pharma stocks fall	25/04/23	RE
India's Ipca Laboratories sinks to 3-yr low after Unichem Lab deal	25/04/23	RE
Indian pharma Ipca Labs to buy over 33% stake in Unichem	24/04/23	RE
Ipca Laboratories Limited made an offer to acquire a 26% stake in Unichem Laboratories Limited for INR 8 billion	23/04/23	CI

Chart Unichem Laboratories Limited

Duration

Period

More charts

Company Profile

Unichem Laboratories Limited is an India-based international, integrated, specialty pharmaceutical company. The Company is focused on product development, process chemistry and manufacturing complex active pharmaceutical ingredients (API) as well as dosage forms. It manufactures and markets pharmaceutical formulations as branded generics as well as generics in several markets across the world. It has several pharma products that address the needs of various therapeutic areas, such as gastroenterology, cardiology, diabetology, psychiatry, neurology, anti-bacterial, anti-infectives and pain management. The Company is also engaged in contract manufacturing with the focus on immediate-release dosage forms, extended-release dosage forms: matrix and pellets, dry powder injections and syrups, novel drug delivery systems, and technology transfer and documentation. Its subsidiaries include Unichem Pharmaceuticals (USA) Inc, Unichem Farmaceutica Do Brasil Lta and Niche Generics Limited UK.

Sector

Pharmaceuticals

Calendar

28/07/2024 - Q1 2025 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Other Pharmaceuticals

	1st Jan change	Capi.
UNICHEM LABORATORIES LIMITED	+34.71%	480M
ELI LILLY AND COMPANY	+37.74%	723B
NOVO NORDISK A/S	+34.81%	595B
JOHNSON & JOHNSON	-2.07%	369B
MERCK & CO., INC.	+20.25%	332B
ABBVIE INC.	+2.99%	282B
ASTRAZENECA PLC	+17.13%	244B
NOVARTIS AG	+10.07%	208B
ROCHE HOLDING AG	-4.13%	205B
AMGEN INC.	+7.43%	166B